MINOCIN
Peakminocycline hydrochloride
NDAINJECTIONINJECTABLE
Approved
Oct 1972
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
CLINICAL PHARMACOLOGY Following a single dose of Minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2.52 to 6.63 mcg/mL (average 4.18 mcg/mL) at the end of infusion and 0.82 to 2.64 mcg/mL (average 1.38 mcg/mL) after 12 hours. In a…
Indications (8)
infections caused by the following Gram-negative bacteriainfections caused by the following Gram-positive bacteriathe treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fevertyphus feverthe typhus groupQ feverrickettsialpoxtick fevers caused by rickettsiae
Clinical Trials (1)
Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
Started Nov 2014
47 enrolled
Acute PainBreast CarcinomaPeripheral Neuropathy
Loss of Exclusivity
LOE Date
Oct 16, 2032
80 months away
Patent Expiry
Oct 16, 2032